Your email has been successfully added to our mailing list.

×
0.102564102564103 0.102564102564103 0.102564102564103 0.102564102564103 0.102564102564103 0.158974358974359 0.217948717948718 0.251282051282051
Stock impact report

FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS

FLEX PHARMA (FLKS) 
Last flex pharma earnings: 8/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.flex-pharma.com/investor-overview
Company Research Source: Business Wire
-- Phase 2 Trials in ALS and CMT to Commence in the US This Quarter -- -- Prioritizing US Phase 2 COMMEND Trial; Exploratory Australian ALS Study to End Early -- BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with serious neurological diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Charcot-Marie-Tooth (CMT), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FLX-787, the Company’s co-activator of TRPA1 and TRPV1, to treat severe muscle cramps in patients with ALS. There are currently no drugs approved in the US for this condition. Fast Track designation is intended to accelerate the clinical development an Show less Read more
Impact Snapshot
Event Time:
FLKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for FLKS alerts
Opt-in for
FLKS alerts

from News Quantified
Opt-in for
FLKS alerts

from News Quantified